Gyroscope Therapeutics Holdings, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, postponed its IPO on Friday, citing market conditions. It had filed to raise $142 million by offering 6.8 million ADSs at a price range of $20 to $22.
The Hertfordshire, United Kingdom-based company was founded in 2016 and booked $1 million in sales for the 12 months ended December 31, 2020. It had planned to list on the Nasdaq under the symbol VISN. Morgan Stanley, Goldman Sachs and Citi were set to be the joint bookrunners on the deal.
